DD, what would be the reasoning by not including a control arm? Cost? Time? Delaying the length of time it takes for investors to find out the drug isn't efficacious?
This might be a good reason that I hadn't thought of yet for why the market just doesn't seem all that interested in ADXS (comparatively speaking). Any insight is appreciated.